Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2020-01-22 Management Reports
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
Bone Therapeutics annonce ses perspectives d’activité pour 2020 et sa position de trésorerie à fin 2019
Management Reports Classification · 95% confidence The document is titled "Bone Therapeutics annonce ses perspectives d'activité pour 2020 et sa position de trésorerie à fin 2019" (Bone Therapeutics announces its 2020 business outlook and cash position as of year-end 2019). It discusses future clinical trial timelines (Phase III for JTA-004, Phase IIb for ALLOB), expected data releases, and provides an update on the cash burn rate and year-end cash position. It also includes a financial calendar listing the 'Rapport annuel 2019' (Annual Report 2019) release date (April 29) and the 'Assemblée générale annuelle 2020' (Annual General Meeting 2020) date (June 10). Since the document itself is an announcement detailing forward-looking statements, operational updates, and financial guidance/cash position rather than the full, audited Annual Report (10-K) or a comprehensive Interim Report (IR), it best fits the category for preliminary results or management commentary preceding the full filings. Given the focus on key financial metrics (cash position, cash burn) and operational milestones/outlook, it aligns closely with an Earnings Release (ER) or Management Discussion & Analysis (MDA). However, since it is explicitly an 'outlook' and cash position update released outside the main earnings report date (March 11 is listed for full 2019 results), and it provides management commentary on strategy and outlook, 'Management Reports' (MDA) is a strong fit, as it contains management's detailed explanation of business trends and outlook. It is not a short announcement linking to a report, so RPA/RNS is less appropriate than MDA.
2020-01-22 French
PR_2019-12-30_BT_CB Denominator_EN_Final.pdf
Share Issue/Capital Change Classification · 98% confidence The document is titled 'Information on the total number of voting rights and shares' and is dated December 30, 2019. It explicitly details changes in the total number of shares, share capital, voting rights, and outstanding convertible instruments (warrants, bonds). This content directly relates to changes in the company's capital structure and ownership notification requirements, specifically referencing Article 15 of the Belgian Law on the publication of major shareholdings. This type of announcement, focusing on the denominator (total shares/voting rights) following a capital event (conversion of bonds), aligns best with the 'Share Issue/Capital Change' category (SHA) or potentially a 'Major Shareholding Notification' (MRQ) if it were purely about crossing a threshold. However, since the core purpose is to report the new total share count resulting from a capital event (issuance of new shares), SHA is the most precise fit. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K).
2019-12-30 English
PR_2019-12-30_BT_CB Denominator_FR_Final.pdf
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information réglementée" (Regulated Information) and is dated December 30, 2019. The core content explicitly announces an increase in the total number of voting rights and shares following the issuance of new shares due to the conversion of convertible bonds. It provides detailed tables comparing the share count and capital structure before and after the issuance, referencing Belgian law regarding significant shareholdings. This type of mandatory disclosure regarding changes in the total number of shares and voting rights (the denominator) is a specific regulatory filing. While it relates to capital structure, the primary focus is the official count update, which aligns best with a general regulatory announcement or a specific capital change notification. Given the explicit focus on the total number of voting rights and shares (the denominator), this is a mandatory disclosure related to capital structure changes. It is not a full Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). It is most closely related to a Share Issue/Capital Change (SHA) or a general Regulatory Filing (RNS). Since it details the resulting share count and voting rights after a capital event (conversion), SHA is a strong candidate, but the structure strongly resembles a mandatory disclosure of the total voting rights count, which often falls under general regulatory announcements if a more specific code isn't available. However, since the event is the issuance of new shares (conversion of debt to equity), SHA (Share Issue/Capital Change) is the most precise fit among the specific codes, as it directly reports the change in the number of shares outstanding.
2019-12-30 French
Bone Therapeutics announces the appointment of Dr. Miguel Forte as CEO to lead the Company into the next phase of development
Board/Management Information Classification · 99% confidence The document is a press release dated December 19, 2019, announcing the appointment of Dr. Miguel Forte as the new Chief Executive Officer (CEO), effective January 1, 2020. This announcement details changes in senior management personnel. According to the definitions, announcements regarding changes in the company's board of directors or senior management fall under the 'Board/Management Information' category, which corresponds to the code MANG. The document is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI). It is a specific personnel announcement.
2019-12-19 English
Bone Therapeutics annonce la nomination du Dr. Miguel Forte en tant que Directeur Général, afin de mener la Société dans la prochaine phase de Développement
Board/Management Information Classification · 99% confidence The document is titled with "Information réglementée" (Regulated Information) and announces the appointment of Dr. Miguel Forte as the new CEO, effective January 1, 2020, succeeding Thomas Lienard. This content directly relates to changes in senior management and the board of directors. This aligns perfectly with the definition for Board/Management Information (MANG). The document is a formal announcement, not a full annual report (10-K) or a quarterly report (IR), nor is it a transcript (CT) or a general regulatory filing (RNS) when a more specific category exists.
2019-12-19 French
20191212_BOTHE_Acte-Notaire.pdf
AGM Information Classification · 98% confidence The document is a formal notarial record (procès-verbal) detailing the proceedings and resolutions of an Extraordinary General Meeting (Assemblée Générale Extraordinaire) of BONE THERAPEUTICS held on December 12, 2019. The primary agenda item (Resolution 1) is the 'RÉDUCTION DES PRIMES D'ÉMISSION ET DU CAPITAL EN APUREMENT DES PERTES' (Reduction of share premiums and capital to write off losses). This type of meeting, which involves major corporate structural changes like capital reduction decided by shareholders, is typically documented in minutes that are either filed as part of a broader corporate governance filing or, if the focus is purely on the meeting itself and its outcomes, it aligns closely with the purpose of an AGM-related document, even though it's an Extraordinary General Meeting (EGM). Since the document records the decisions, voting results, and formal ratification of resolutions made during a shareholder meeting, the most appropriate classification among the provided options is AGM-R (AGM Information), as EGMs fall under the general scope of shareholder meetings documented for regulatory/corporate record purposes, distinct from standard financial reports (10-K, IR) or simple announcements (RPA, RNS). The document is comprehensive, not just an announcement of a meeting.
2019-12-12 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.